NCT02603510View on ClinicalTrials.gov

Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

SAR342434

"Pharmaceutical form:solution~Route of administration: subcutaneous"

DRUG

insulin lispro

"Pharmaceutical form:solution~Route of administration: subcutaneous"

Trial Locations (2)

72205

Investigational Site Number 840002, Little Rock

80262

Investigational Site Number 840001, Denver

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT02603510 - Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion | Biotech Hunter | Biotech Hunter